ADXS
Advaxis, Inc.
Halal Rating :
Last Price
$0.00
Last updated:
Market Cap
-
7D Change
-100.0%
1 Year Change
-100.0%
Company Overview
Industries
Exchange
Next Earnings Date
Advaxis, Inc. was a clinical-stage biotechnology company focused on developing cancer immunotherapies. However, in February 2023, the company merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals, Inc. The combined company now focuses on developing targeted therapies for rare tumors and aggressive cancers.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2023 | $9000.0 | $8.49m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Advaxis, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.